Establishment of novel cell therapy for diabetes by introducing angiogenic peptide

2016 Fiscal Year Final Research Report

• Project/Area Number: 15K15469
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: General surgery
• Research Institution: Tohoku University
• Principal Investigator: Goto Masafumi 東北大学, 医学系研究科, 教授 (50400453)
• Research Collaborator: NOKIHARA Kiyoshi
• Project Period (FY): 2015-04-01 – 2017-03-31
• Keywords: 移植・再生医療 / 血管新生 / 膵島移植 / ペプチド

Outline of Final Research Achievements

Subcutaneous islet transplantation is associated with minimal invasiveness, replicability, and ready removability, but poor vascularization. Thus, the optimization of the prevascularization procedures is crucial for improving the outcomes. Therefore , in the present study, we first evaluated the effectiveness of angiogenic peptide. Although rather small amount of angiogenic peptide was effective for constructing vascular network under the skin, high dose of angiogenic peptide was required in order to improve the engraftment of subcutaneous islet transplantation. Then, we focused on recombinant peptide, which includes a lot of RGD constructions. It was proved that recombinant peptide was effective for inducing vascular network under the skin, and that the outcome of subcutaneous islet transplantation using recombinant peptide was almost comparable with that of current standard intraportal islet transplantation.

Free Research Field

移植外科、細胞移植